Is Mimedx Group Incorporated (NASDAQ:MDXG)’s Fuel Running Low? Reports Show More Sellers

February 15, 2018 - By Maria Brooks

 Is Mimedx Group Incorporated (NASDAQ:MDXG)’s Fuel Running Low? Reports Show More Sellers

Investors sentiment decreased to 1.97 in Q3 2017. Its down 0.05, from 2.02 in 2017Q2. It dropped, as 21 investors sold MiMedx Group, Inc. shares while 44 reduced holdings. 48 funds opened positions while 80 raised stakes. 77.22 million shares or 15.28% more from 66.99 million shares in 2017Q2 were reported.
Jpmorgan Chase Co, New York-based fund reported 46,543 shares. Morgan Stanley accumulated 0.01% or 1.54M shares. Amalgamated Comml Bank reported 14,436 shares or 0.01% of all its holdings. Parallax Volatility Advisers Limited Partnership holds 83,419 shares. Verition Fund Mgmt Limited Co reported 0.04% in MiMedx Group, Inc. (NASDAQ:MDXG). Blackrock invested 0.01% in MiMedx Group, Inc. (NASDAQ:MDXG). Moreover, Rice Hall James Ltd Llc has 0.08% invested in MiMedx Group, Inc. (NASDAQ:MDXG) for 142,957 shares. Massachusetts Fincl Ser Ma invested 0% in MiMedx Group, Inc. (NASDAQ:MDXG). Virginia Retirement Sys Et Al holds 75,400 shares. Lincoln Natl reported 0.01% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG). Citigroup Inc invested in 172,055 shares. Moreover, Royal Natl Bank Of Canada has 0% invested in MiMedx Group, Inc. (NASDAQ:MDXG) for 225,804 shares. Aqr Cap Management reported 0% in MiMedx Group, Inc. (NASDAQ:MDXG). Boston Advisors Ltd invested in 0.01% or 55,183 shares. Northern has 0% invested in MiMedx Group, Inc. (NASDAQ:MDXG) for 1.38 million shares.

The stock of Mimedx Group Incorporated (NASDAQ:MDXG) registered an increase of 5.56% in short interest. MDXG’s total short interest was 41.33M shares in February as published by FINRA. Its up 5.56% from 39.15M shares, reported previously. With 1.92 million shares average volume, it will take short sellers 22 days to cover their MDXG’s short positions. The short interest to Mimedx Group Incorporated’s float is 42.25%.

The stock decreased 3.51% or $0.56 during the last trading session, reaching $15.4. About 1.77M shares traded. MiMedx Group, Inc. (NASDAQ:MDXG) has risen 107.87% since February 15, 2017 and is uptrending. It has outperformed by 91.17% the S&P500.

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. The company has market cap of $1.71 billion. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. It has a 49.52 P/E ratio. The companyÂ’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.

MiMedx Group, Inc. (NASDAQ:MDXG) Ratings Coverage

Among 8 analysts covering MiMedx Group (NASDAQ:MDXG), 6 have Buy rating, 2 Sell and 0 Hold. Therefore 75% are positive. MiMedx Group had 27 analyst reports since July 29, 2015 according to SRatingsIntel. Needham maintained the stock with “Buy” rating in Thursday, January 18 report. The stock of MiMedx Group, Inc. (NASDAQ:MDXG) has “Buy” rating given on Friday, August 18 by Piper Jaffray. The firm has “Buy” rating by Canaccord Genuity given on Friday, December 18. Needham maintained MiMedx Group, Inc. (NASDAQ:MDXG) rating on Monday, January 8. Needham has “Buy” rating and $21.0 target. The firm has “Underweight” rating given on Tuesday, May 23 by First Analysis. The rating was maintained by Needham with “Buy” on Wednesday, August 30. The firm earned “Buy” rating on Thursday, July 13 by Piper Jaffray. The rating was maintained by Needham with “Buy” on Wednesday, December 13. Needham maintained MiMedx Group, Inc. (NASDAQ:MDXG) on Friday, July 14 with “Buy” rating. The stock has “Buy” rating by Piper Jaffray on Wednesday, December 13.

More news for MiMedx Group, Inc. (NASDAQ:MDXG) were recently published by:, which released: “MiMedx Announces the Enrollment of the First Patients in the Phase 3 Clinical …” on January 17, 2018.‘s article titled: “MiMedx Group (MDXG) Provides Commentary on Magistrate Recommendation in …” and published on January 18, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.